Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT04100434
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT04100434
-
- Other papers using this trial's data
- Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04100434. Randomized; double masking; primary purpose treatment. Start 2021-01-01 (anticipated); primary completion 2022-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
- Acronym
- EMSIACS
- Condition
- Acute Coronary Syndrome
- Condition
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Tianjin Chest Hospital
Record details
- Record id
cardio:ct-nct04100434- Content hash
9c5dbf1caca42fb0d464e025bbea1475ce11a32f235ab0481a203b1aac5321ae